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Tetanus vaccination is one of the most frequently administered vaccines as a part of wound management
and was also found to be associated with increased serum IgE levels. We hypothesized that the vaccina-
tion modifies the risk of allergic diseases through epigenetic changes such as DNA methylation.
Method: Data on tetanus vaccination between 10 and 18 years of age was collected from a birth cohort
established on the Isle of Wight UK in 1989. DNA methylation data were collected from individuals at
different ages (at birth [n = 30], age 10 [n = 34], age 18 [n = 245] and during pregnancy [n = 121]) using
the Illumina Infinium HumanMethylation450 K array. Firstly, we performed an epigenome-wide
screening to identify cytosine-phosphate-guanine sites (CpGs) associated with tetanus vaccination in
18-year-olds. Secondly, we tested their association with asthma, allergic sensitization, eczema, serum
IgE and pulmonary lung function (FVC, FEV1, FEV1/FVC, and FEF25-75%). We then described changes
in the methylation of the selected CpG sites over age, and by vaccination status.
Results: Tetanus vaccination was found to be associated with decreased methylation of cg14472551
(p value 0.5  105, FDR-adjusted p value 2.1  104) and increased methylation of cg01669161 (p value
0.0007, FDR-adjusted p value 0.014). Both CpGs, in turn, were associated with decreased risk of asthma at
18 years of age. Cg14472551 is located in an intron of KIAA1549L, whose protein binds to a B-cell com-
mitment transcription factor; cg01669161 is located between an antisense regulator of the proteasome
assembly chaperone PSMG3, and TFAMP1, a pseudogene. Increased methylation of cg01669161 was also
associated with decreased serum IgE levels.
Conclusion: DNA methylation changes following tetanus vaccination may offer a novel prospect to
explain a differential occurrence of asthma in adolescence.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vaccination is related to widespread immunity and eradication
of many infectious diseases [1,2]. Vaccines induce acquired activeimmunity, which initiates a cascade of differentiation of immune
cells into effector and memory cells [3,4]. Vaccines, along with
booster doses generate immune memory cells to maintain long-
lasting or lifelong protection against a specific antigen [4,5]. The
tetanus vaccine has adjuvant effects and has been associated with
upregulating total and specific immunoglobulin E (IgE) antibodies
[6,7], which in turn play a vital role in allergic diseases.
Effects of vaccination on the prevalence of allergic diseases
remain in debate. To assess their association, several studies have
been conducted [7–12]. Scheduled childhood vaccination of DTP
(diphtheria, tetanus, pertussis) has been reported to be associated
6494 V.D. Janjanam et al. / Vaccine 34 (2016) 6493–6501with increased risk of asthma [10]. Similar findings were reported
in children and adolescents (2 months to 16 years of age), conclud-
ing that DTP and tetanus vaccination (TVac) were associated with
increased risk of allergies [7]. Conversely, the DPPT (Diphtheria,
Polio, Pertussis, Tetanus) and MMR (measles, mumps, and rubella)
vaccines were not linked with physician diagnosed asthma or
eczema in children in one birth cohort study [11]. A lack of
associations was also reported in a population-based cohort study
(TAHS-Tasmanian Longitudinal Health Study), which followed
participants from 7 to 45 years of age [9]. Thus, whether
allergy and asthma are influenced by vaccination remains in
contention.
Epigenetic processes such as DNA methylation (DNA-M) may
provide a mechanistic link between vaccination and the
occurrence of disease. DNA-M, the addition of a methyl group
to a cytosine followed by a guanine (CpG sites, CpGs), is known
to mediate the effect of environment at transcriptional levels,
and also has well-evidenced connections to allergic disease
[13]. An immunological study suggested that epigenetic changes
in vaccine-induced memory CD4 and/or CD8 T cells act as
on-off-on switches for immune responses after re-exposure to
antigen [14]. A recent study demonstrated an overall decrease
in global DNA-M in vaccinated compared to non-vaccinated
chickens [15].
Asthma is a common chronic inflammatory disease of the air-
ways characterized by wheezing, chest tightness and shortness of
breath. It has been suggested that DNA–M may modulate the reg-
ulation of genes that are associated in the pathogenesis of asthma
and allergy [13,16–19].
We hypothesized that TVac could alter the methylation of
specific CpGs, influencing allergic disease risk. We performed an
epigenome-wide association study (EWAS) to identify CpGs differ-
entially methylated between 18-year old children vaccinated and
non-vaccinated between 10 and 18 years. Next, we analyzed
whether tetanus vaccination-associated CpGs are associated with
allergy and asthma. To further explore the potential effect of TVac,
we describe differential DNA-M of specific CpGs at different ages
(at birth, age 10, 18 years and during pregnancy) and across chil-
dren who were vaccinated and non-vaccinated between 10 and
18 years.2. Methods
2.1. Study population
A whole population birth cohort was established on the Isle of
Wight, UK in 1989 to study the natural history and etiology of
asthma and allergic diseases. The study was approved by the local
research ethics committee (NRES Committee South Central–Hamp-
shire B). Of 1536 eligible children born between January 1, 1989
and February 28, 1990, 1456 were enrolled after excluding adop-
tions, infant deaths and refusals. Written informed consents were
received from enrolled parents (F0). Their children (F1) were fol-
lowed up with detailed questionnaires at ages 1, 2, 4, 10 and
18 years. Guthrie cards (blood collected within 7 days of birth,
n = 30) and peripheral blood samples at age 10 (n = 34) and 18
(n = 370) years were collected from randomly selected subjects
for DNA-M profiling. Pregnant F1 participants and their partners
were recruited and followed up at 12, 20 and 28 weeks of preg-
nancy with detailed questionnaires. During pregnancy, peripheral
blood samples from pregnant F1 participants (n = 121) were col-
lected for epigenome-wide DNA-M profiling. Nearly all the chil-
dren (94.3%) in our cohort have been vaccinated at 10 years of
age according to the recommended UK immunization schedule
[32].2.2. DNA methylation
DNA was extracted from Guthrie cards using a procedure based
on that described by Beyan et al. [20], and from whole blood using
a standard salting out procedure [21]. In all samples up to 1 lg of
DNAwas bisulfite-treated for cytosine to thymine conversion using
the EZ 96-DNA methylation kit (Zymo Research, CA, USA), follow-
ing the manufacturer’s standard protocol. DNA-M was assessed
using the Illumina Infinium HumanMethylation450 Beadchip (Illu-
mina, Inc., CA, USA). Arrays were processed using a standard proto-
col [22], with multiple identical control samples assigned to each
bisulfite conversion batch to assess assay variability. Samples were
randomly distributed on microarrays to control for batch effects.
The beadchips were scanned using a BeadStation, and the methy-
lation level (b value) was calculated for each queried CpG locus
using the Methylation module of BeadStudio software. Beta values
represent the proportions of methylated (M) over the sum of
methylated (M) and unmethylated (U) sites (b = M/[c + M + U])
with c being a constant to prevent dividing by zero [23].
2.3. Pre-processing DNA-M data
The detection p-values reported by Genome Studio were used
as a QC measure of probe performance in our study. CpGs with a
detection p-value > 0.01 in > 10% of samples were removed [24].
Bioconductor IMA (Illumina methylation analyzer) and Com-Bat
statistical computing packages were used for pre-processing
DNA-M data and inter-array variation adjustments respectively
[25,26]. We excluded all CpGs with a potential single nucleotide
polymorphism (SNP) in the binding region or at base-pair exten-
sion according to dbSNP137, because probe-SNPs may interfere
with DNA-M measurement (Fig. 1).
2.4. Exposure
Information on vaccination at 18 years was collected from ques-
tion ‘‘Have you had the following immunizations since you were
10 years old?”, which included tetanus, BCG, diphtheria, polio
and other vaccinations, answered by the individuals at the
18-year follow up.
2.5. Outcome variables
In the first step, we performed epigenome-wide screening for
differentially methylated CpGs that were associated with TVac. In
the second step, tetanus vaccination-associated CpGs were tested
for association with asthma, eczema, and allergic sensitization
(Fig. 1). Asthma at age 18 years was defined by ‘‘ever had asthma”
as well as either ‘‘wheezing or whistling in the chest during the
previous 12 months” or ‘‘current treatment for asthma”. Allergic
sensitization at age 18 years was determined by positive skin prick
test response (P3 mm larger than negative control) using 14 com-
mon food and aeroallergens (ALK-Albello, Horsholm, Denmark)
[27]. Eczema was defined as chronic or chronically relapsing, itchy
dermatitis lasting more than six weeks with characteristic mor-
phology and distribution [28], following Hanifin and Rajka criteria
[29]. In the third step, to determine the consistency, we tested
disease-related markers such as serum IgE level and lung function
measurements at age 18. Serum IgE was assessed using Immuno-
cap (Phadia, Uppsala, Sweden), designed to measure IgE between
2.0 and 1000 kU/L in serum. Regarding lung function, forced vital
capacity (FVC), forced expiratory volume in one second (FEV1),
and forced expiratory flow (FEF25%-75%) were measured using a
Koko spirometer and software with a portable desktop device
(both PDS Instrumentation, Louisville, KY, USA). Spirometry was
performed and evaluated according to the American Thoracic
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Fig. 1. Flow chart illustrating the identification of CpG sites that are associated with Tetanus vaccination, asthma, eczema, and allergic markers.
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tory infection for two weeks, withhold steroids intake and were
advised to abstain from any b-agonist medication for six hours
and caffeine intake for at least 4 h. The fraction of exhaled nitric
oxide (FeNO) was measured (Niox mino, Aerocrine AB, Solna,
Sweden) according to ATS guidelines [30] as described by Scott
et al. [31].
2.6. Potential confounders
Variables potentially associated with allergic disorders and/or
DNA-M were considered to be potential confounders, including
gestational smoking, chest infections at age one and two years,
duration of breast feeding (in weeks), sex of the child, current
smoking status, farm exposure and number of days of exercise at
18 years of age. Regarding lung function, we controlled for sex of
the child, gestational smoking, duration of breast feeding (weeks),
and height (in centimeters) at 18 years of age. Duration of breast
feeding information was collected from the questionnaire
answered by F0 mothers at age 1 and 2 years. Chest infection atage one and two years of ages were defined by ‘‘recurrent chest
infection one year” and ‘‘recurrent chest infections at two years”
of age. Information regarding gestational smoking, current smok-
ing status, daily physical activities like number of days of exercise,
height of the individuals were obtained from the detailed question-
naire answered at age 18 years follow up. Farm exposure of the
individual was ascertained by ‘‘Have you ever lived on farm”.
2.7. Statistical analysis
The sample analyzed in this work was assessed for its repre-
sentability of the total cohort. M-values (logit transformed b val-
ues) were used for epigenome-wide screening [33]. The
ttScreening, R computing package (R version 3.1.1) [34] was
applied to screen CpGs that are potentially associated with the sta-
tus of TVac at 18 years of age. The analytical methods implemented
in this computing package facilitates a screening process that fil-
ters the non-informative CpGs through 100 iterations of a
training-and-testing process with robust regressions. By building
a more generalized model than conventional EWAS methods,
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methods [34]. In robust regressions, DNA-M is taken as the depen-
dent variable and TVac and covariates (in this case, the potential
confounding variables) are the independent variables. A CpG was
selected as an informative site if it showed statistical significance
in at least 65% of training and testing samples. CpGs identified as
informative were further tested in models including additional
confounders to intensively test their association with the status
of TVac at 18 years of age. We applied log-linear regression models
(GENMOD procedure in SAS 9.4) to estimate risk ratios for asthma,
allergic sensitization, and eczema at 18 years of age. To adjust for
different sample size contributed by girls and boys we used weight
statement and controlled for sex. In all analyses, including EWAS
and associations of candidate CpGs with asthma, and other allergic
diseases, all p-values were adjusted for false discovery rate (FDR)
[35] with a p-value of 6 0.05 being statistically significant.
To further illustrate our findings, the CpGs linked with asthma,
allergic sensitization and/or eczema were categorized into four
groups based on equidistant intervals of methylations across the
range of the methylation. To evaluate the functional role of these
associations, we investigated whether these CpGs are also linked
with lung function measurements and serum IgE levels (log-
transformed) at age 18 years controlling for duration of breast
feeding, sex, height, physical activity, and smoking status at
18 years of age. To this end, we conducted linear regression models
with DNA-M as the dependent variable. All regression analyses
(log-linear and linear models) were performed using DNA-M data
at 18 years of age (n = 370). EWAS analyses were performed in RTable 1
Asthma, eczema, allergic sensitization, serum IgE, spirometric measurements, tetanus vac
Factor Study population
Girls (%) (n = 750) Population
analyzed (%)
Tetanus vaccination at age 18 Yes 62.1 (466) 73.5 (180)
No 15.4 (116) 15.9 (65)
Missing 22.4 (168) 10.6 (26)
Maternal smoking status Yes 25.1 (188) 19.2 (47)
No 74 (555) 80.4 (197)
Missing 0.9 (86) 0.4 (1)
Do you currently smoke (at age 18) Yes 25.6 (192) 25.7 (63)
No 60.6 (455) 73.8 (181)
Missing 13.73 (103) 0.41 (1)
Chest infection at one years of age Yes 5.1 (38) 7 (17)
No 70.1 (526) 85.3 (209)
Missing 20 (150) 8 (19)
Chest infection at two years of age Yes 9.8 (74) 11.4 (28)
No 70.1 (526) 72.6 (178)
Missing 20 (150) 15.9 (39)
Have you ever lived on farm Yes 7.1 (53) 7.3 (18)
No 78.8 (591) 92.6 (227)
Missing 12.5 (94) 0.5 (2)
Asthma Yes 17.1 (128) 14.29 (35)
No 70.8 (531) 85.7 (210)
Missing 12.1 (91)
Allergic sensitization Yes 21.2 (159) 31 (76)
No 38.2 (287) 67.7 (166)
Missing 40.5 (304) 1.2 (3)
Eczema Yes 14.3 (107) 15.1 (37)
No 73.2 (549) 84.4 (207)
Missing 12.5 (94) 0.41 (1)
Mean (5%–95% CI)
Days of exercise (days/week) 2.1 (0–7) 2.5 (0–7)
Duration of breast feeding (week) 14 (0–40) 15.2 (0–40)
Height (cm) 165 (154.5–175) 165 (154–17
Serum IgE (kU/L) 283 (102 to 1351) 226.2 (8.9–1
FVC at 18 years of age (L) 3.9 (3.1–4.8) 4 (3.1–5)
FEV1 at age 18 years (L) 3.5 (2.7–4.1) 3.5 (2.8–4.3)
FEV1/FVC at age 18 years 0.87 (0.7–0.9) 0.87 (0.75–0.
FEF 25–75% (Liter per second) 3.9 (2.5–5.4) 4 (2.5–5.4)(R package 3.1.1 version) log-linear and linear regression were per-
formed using the SAS statistical package, Version 9.4 (SAS Institute,
Cary, NC, USA).
Finally, we examined differential methylation of tetanus
vaccination-associated CpGs at different ages in the F1 generation
and in vaccinated and non-vaccinated individuals. In this descrip-
tive part covering four periods of life, we had to use different sam-
ple sizes of female participants that were available to us: n = 34 at
birth, n = 30 at age 10, n = 245 at age 18, n = 121 during pregnancy.
In addition, we describe the methylation changes in five women,
who participated in all of the above four periods.
3. Results
We found no significant difference between the population ana-
lyzed, both female (n = 245) and male participants (n = 125), with
methylation data available at 18 years of age with the participants
of the whole cohort (750 females and 786 males) (Table 1). Among
female and male participants in the subsample, 73.5% and 71.2%
had TVac, 19.2% and 22.4% had a history of maternal smoking,
7.0% and 6.4% had chest infection at age one year, and 14.2% and
12.8% of them had asthma at 18 years of age respectively.
A total of 53 CpGs were identified in the EWAS, 11 of which
were affected by a probe-SNP and thus were excluded (Fig. 1). After
adjusting for physical activity and farm exposure, which may be
related to TVac, and controlling for FDR, two further CpGs were
excluded and a set of 40 CpGs were retained (Table 2). Of these
40 candidate CpGs, cg14472551 (p value 0.5  105, FDR p valuecination and potential confounders at age one, two and 18 years of age.
Study population
(n = 245)
p-value Boys (%) (n = 786) Population
analyzed (%) (n = 125)
p-value
0.5 63.3 (498) 71.2 (89) 0.14
10.1 (79) 16.8 (21)
26.5 (209) 12 (15)
0.054 24.9 (196) 22.4 (28) 0.53
74 (582) 76.8 (96)
1 (8) 0.8 (1)
0.25 22.3 (176) 25.6 (32) 0.79
57.8 (455) 72 (90)
19.7 (155) 2.4 (3)
0.32 8.2 (63) 6.4 (8) 0.46
80 (628) 84.8 (106)
12.1 (95) 8.8 (11)
0.63 10.1 (80) 11.2 (14) 0.9
67.4 (530) 74.4 (93)
22.3 (176) 14.4 (18)
0.66 5.3 (42) 8 (10) 0.53
75.5 (594) 90.4 (113)
19.1 (150) 1.6 (2)
0.074 13.1 (103) 12.8 (16) 0.37
69 (543) 87.2 (109)
17.8 (140)
0.26 24.6 (194) 40 (50) 0.17
27.1 (213) 58.4 (73)
48.2 (379) 1.6 (2)
0.67 6.8 (54) 92.8 (116) 0.68
76 (597) 7.2 (9)
17.1 (135)
p-value Mean (5%–95% CI) p-value
0.07 3.3 (0–7) 3.8 (0–7) 0.06
0.16 – –
6) 0.44 178.1 (167–189) 177.4 (167–187.3) 0.29
165) 0.56 372.7 (102 to 032.1) 499.2 (14.8–21233) 0.08
0.07 5.3 (4.2–6.6) 5.3 (4.1–6.6) 0.99
0.08 4.6 (3.6–5.6) 4.6 (3.5–5.6) 0.58
98) 0.65 0.86 (0.86–0.74) 0.87 (0.77–0.99) 0.59
0.33 4.9 (3.2–6.8) 5.1 (3.4–6.9) 0.42
Table 2
Estimates of the tetanus vaccination effect of originally selected CpG sites based on ttScreening and additionally controlled of confounders in linear models.
CpG sites Selection probability Estimate# p-value Estimate after adjusting* p-value after adjusting* FDR adjusted p-value
cg11987154 80 0.1788 3.92E06 0.1994 2.00E07 1.02E05
cg16109089 81 0.1303 6.60E06 0.1324 1.00E05 0.0001
cg00756062 76 0.1927 1.00E05 0.1921 1.00E05 0.0001
cg23901896 72 0.2136 1.22E05 0.2022 3.00E05 0.0001
cg11709763 72 0.2054 1.26E05 0.2102 3.00E06 4.79E05
cg14472551 79 0.3246 1.26E05 0.2974 0.004 0.0053
cg19702771 82 0.1309 1.46E05 0.1452 1.00E04 0.0004
cg12149319 70 0.1466 1.70E05 0.1726 3.00E06 4.79E05
cg03628403 75 0.1364 2.41E05 0.0946 0.003 0.0037
cg01669161 67 0.1467 2.84E05 0.1716 6.00E04 0.001
cg11902863 67 0.1209 2.96E05 0.0843 0.034 0.0359
cg10365178 75 0.1528 3.00E05 0.1021 0.003 0.0041
cg17022393 68 0.1774 3.18E05 0.1695 7.00E05 0.0002
cg02874226 73 0.1696 3.19E05 0.1641 4.00E05 0.0002
cg27393285 70 0.2855 3.30E05 0.2281 5.00E04 0.001
cg07906078 78 0.2102 3.42E05 0.1995 6.00E05 0.0002
cg25965290 76 0.1863 3.44E05 0.1704 2.00E04 0.0004
cg24383418 71 0.1239 4.24E05 0.0869 0.14 0.1401
cg02464866 72 0.1971 4.80E05 0.1578 0.001 0.0015
cg14225485 65 0.1525 4.98E05 0.1231 0.009 0.0098
cg22455614 71 0.1192 5.38E05 0.0894 0.004 0.0053
cg24926780 75 0.1385 5.50E05 0.1251 4.00E04 0.0009
cg21722418 66 0.3205 6.90E05 0.2934 2.00E04 0.0004
cg09629053 69 0.2411 7.07E05 0.2416 4.00E05 0.0001
cg00147244 67 0.1739 7.10E05 0.1427 0.002 0.0025
cg00777375 67 0.1101 7.47E05 0.0851 0.006 0.0063
cg05445006 69 0.0963 7.71E05 0.0571 0.065 0.0663
cg03587557 72 0.1957 7.83E05 0.1695 5.00E04 0.0011
cg27297043 65 0.1441 8.27E05 0.1304 0.002 0.0024
cg02535684 66 0.2837 8.39E05 0.2404 6.00E04 0.001
cg11027772 66 0.1348 8.61E05 0.1202 1.00E03 0.0015
cg24171875 67 0.101 9.10E05 0.0585 0.028 0.0303
cg25119654 73 0.1635 0.0001 0.1824 4.00E05 0.0001
cg01844176 69 0.2019 0.00011 0.1991 2.00E04 0.0005
cg11196333 67 0.2486 0.00012 0.2525 1.00E04 0.0004
cg11304283 69 0.1999 0.00015 0.1987 6.00E04 0.001
cg00639041 70 0.1107 0.00016 0.1014 5.00E04 0.001
cg20409368 65 0.2266 0.00017 0.2014 0.001 0.0015
cg26525486 65 0.1941 0.00019 0.1453 0.005 0.0062
cg02926601 66 0.1875 0.00022 0.2021 1.00E04 0.0004
cg16027403 66 0.1324 0.00025 0.1195 7.00E04 0.0011
cg10893220 65 0.1291 0.00029 0.1188 5.00E04 0.0011
# Statistically controlled for sex and cell proportions (CD4, granulocytes, eosinophils, B-lymphocytes, natural killer cells, monocytes) at 18 years of age.
* Statistically controlled for sex, farm exposure and physical activity at 18 years of age.
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both statistically significant and associated with asthma status at
18 years. TVac was associated with the increased methylation of
cg01669161 and decreased methylation of cg1447251. Both CpGs
are in turn associated with decreased risk of asthma.
To demonstrate the relative risk for asthma related to differen-
tial methylation of these two CpGs, we categorized each CpG in
four groups using equidistant intervals of methylations across
the range of the methylation (Table 3). Methylation of
cg14472551 (methylation (b value) > 0.55) increased the relative
risk of asthma RR = 4.74 (95% CI 1.91–11.75, p = 0.0008) (Table 3).
For cg01669161, a decreased methylation (methylation (b value)
< 0.45) was associated with increased relative risk of asthma
RR = 2.7 (95%CI 1.2–6.41 p = 0.016, Table 3). In addition, decreased
methylation of cg01669161 was associated with increased serum
IgE (log10) levels (Estimate (SE): 2.48 (1.23), p = 0.045).
We further inspected methylation changes of cg14472551 and
cg01669161 at different ages in five female participants with com-
plete follow-up data on DNA-M. In particular, we compared the
methylation of these two CpGs among vaccinated (n = 269) and
non-vaccinated individuals (n = 60) using the median methylation
values (b values). In this descriptive analyses (Fig. 2) we observed
that methylation of cg14472551 was higher at birth (b value > 0.6)than at 10 (b value < 0.44) and 18 years (b value < 0.43).
Cg14472551 showed the lowest methylation during pregnancy (b
value < 0.34). Cg14472551 was lower methylated in vaccinated
individuals (n = 269, b value < 0.43) while higher methylated in
non-vaccinated individuals (n = 60, b value < 0.47). cg01669161
also showed a difference among vaccinated and non-vaccinated
individuals: higher methylation was observed in vaccinated (b
value > 0.49) compared to non-vaccinated individuals (b
value > 0.47). However, cg01669161 was lower methylated at birth
(b value < 0.36), but higher at age 18 (b value > 0.42) and during
pregnancy (b value > 0.46).
To further illustrate the effect of the TVac associated CpGs on
the prevalence of asthma, we dichotomized the methylation at
the median level. Interestingly, the prevalence of asthma among
vaccinated individuals (13%) was lower compared to non-
vaccinated (22%) however not statistically significant (p = 0.07)
(Fig. 3). When we stratified this association by cg14472551 (low
vs. high methylated), we found a higher prevalence of asthma
among higher methylated children with no vaccination
(p = 0.041). In vaccinated children, no increased prevalence of
asthma was detected. For cg01669161 the prevalence of asthma
was lower among children with higher methylation; however,
using a crude dichotomization, the difference did not gain statisti-
Table 3
Effect of methylation of cg14472551 and cg01669161 on asthma, serum IgE and lung function measurements at 18 years of age.
cg14472551 cg01669161
Proportion of methylation Risk ratio 95% CL+
Asthma*
p-value Proportion of methylation Risk ratio 95% CL+
Asthma*
p-value
0–0.35 (n = 70) Reference 0–0.45 (n = 88) 2.78 1.2–6.41 0.016
0.35–0.45 (n = 139) 0.91 0.32–2.56 0.85 0.45–0.50 (n = 124) 0.96 0.38–2.41 0.93
0.45–0.55 (n = 104) 2.67 1.08–6.62 0.033 0.50–0.55 (n = 104) 1.15 0.46–2.89 0.75
>0.55 (n = 57) 4.74 1.91–11.75 0.0008 >0.55 (n = 54) Reference
Parameter estimate Standard error p-value Parameter estimate Standard error p-value
Serum IgE (log transformed)# 0.69 0.52 0.19 2.48 1.23 0.04
FVC# (L) 0.46 0.28 0.11 0.49 0.53 0.36
FEV1# (L) 0.27 0.24 0.28 0.13 0.47 0.78
FEV1/FVC# 0.006 0.04 0.87 0.15 0.08 0.06
FEF25-75%# (L/s) 0.35 0.55 0.52 1.35 1.04 0.19
* Statistically controlled for sex, gestational smoking, current smoking status, chest infection at one and two years of age, duration of breast feeding, farm exposure and
number of days of exercise at age 18 years.
# Statistically controlled for sex, gestational smoking, duration of breast feeding (weeks), farm exposure, height at age 18 and number of days of exercise at 18 years of age,
cell types.
+ 95% confidence internals.
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Fig. 2. Median Methylation of cg14472551 and cg01669161 at different ages in different subsamples and for five women with complete follow-up from Guthrie cards to
pregnancy. In these subgroups, all participants at age 10 years have received tetanus vaccination. The following table represents the sample size at different ages represented
in the graph. Cg14472551 showed lower methylation until age 10 further increased by age 18, followed by lower methylation during the pregnancy. It showed a low
methylation in vaccinated individuals compared to the non-vaccinated individuals and during pregnancy. Cg01669161 showed a constant increased in the methylation over
time with high methylation in vaccinated individuals and during pregnancy.
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Fig. 3. The prevalence of asthma among vaccinated and non-vaccinated with lower and higher methylations individuals at 18 years of age. Higher and lower methylation
groups were grouped based on the median methylation (b values) values. ⁄ncg14472551 6 0.43 considered lower methylated and ncg14472551 > 0.43 as higher methylated.
#ncg01669161 6 0.49 considered lower methylated and ncg01669161 > 0.49 as higher methylated. The prevalence of asthma is lower in vaccinated compared to non-
vaccinated individuals. The prevalence of asthma is higher in non-vaccinated individuals whose cg14472551 methylation was higher while the prevalence was lower in
vaccinated individuals. Individuals with higher methylation of cg01669161 has showed lower prevalence of asthma compared to lower methylation in both vaccinated and
non-vaccinated individuals.
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(Fig. 2), we also observed that cg14472551 showed lower and
cg01669161 higher methylation during pregnancy compared to
other ages.4. Discussion
Our study demonstrated that epigenetic changes due to vacci-
nation can alter the risk of asthma at age 18 years. In an
epigenome-wide screening we found that TVac was associated
with differential DNA-M: decreased methylation of cg14472551
(KIAA1549L gene) and increased methylation of cg01669161 (inter-
genic region of PSMG3 and TFAMP1) at age 18 years. We further
investigated the association of these two CpGs with asthma and
other allergic diseases. Following the effect of TVac on these two
CpGs, both a higher and lower methylation of cg14472551 and
cg01669161, respectively, were associated with an increased risk
of asthma at 18 years of age. To our knowledge this is the first
study to illustrate that TVac is associated with differential methy-
lation which inturn has a protective effect on asthma in
adolescence.
The locations of these two CpGs suggest a potentially functional
connections to allergic disease. Cg14472551 is located upstream of
the transcriptional start site of KIAA1549L (also known as C11orf41)
on chromosome 11. The KIAA1549L protein is 1849 amino acids
long and contains highly conserved regions [36,37]. KIAA1549L acts
a fusion partner of PAX5, a transcription factor critical for B-cell
commitment and maintenance [37]. From Gene Ontology annota-
tions (http://www.uniport.org/uniport/Q6ZVL6) it was found that
KIAA1549L is involved in the biological process of upregulation,
stimulation, and activation of defense response to virus by the
host. Since DNA-M and gene expression are inversely correlated
a lower methylation on TSS may upregulate the expression of
KIAA1549L and enhance host immunity.
Cg01669161 is located in the intergenic region (24,848 base
pairs) between an antisense regulator of the proteasome assembly
chaperone PSMG3 and TFAMP1 genes (a non-coding RNA) on chro-
mosome 7. It is in close proximity (3000 base pairs downstream) of
PSMG3 (Proteasome assembly chaperon 3). Proteasomes are respon-
sible for processing antigens for presentation on the cell surface, an
essential step of vaccination-induced immunity. Close proximity of
cg01669161 PSMG3 may thus explain its role in TVac and allergy.To further evaluate the functional role of these two CpGs, we
investigated their association with lung function measurements
and serum IgE. Serum IgE plays a key role in type I hypersensitivity
(B-cell-induced IgE-mediated immune response) reactions such as
allergy and asthma [38]. It also has an important role upstream of
the cascade of reaction in inflammatory response in skin and lungs.
Interestingly, higher methylation of cg01669161 is also associated
with decreased serum IgE levels, which may potentially contribute
to the protective effect against asthma.
For descriptive purposes, we also examined the differential
methylation of these two CpGs at four age periods in female sub-
groups of the F1 generation using different (smaller) sample sizes.
We observed that cg14472551 showed a higher methylation at
birth followed by a decrease methylation over age while
cg01669161 represented a lower methylation at birth followed
by increased methylation over age. Cg14472551 was lower and
cg01669161 was higher methylated during pregnancy and in vac-
cinated individuals, in agreement with the findings from the
regression analyses. In five women with complete follow up the
differential methylation of the two CpGs are in agreement with
the cross-sectional findings of different samples.
After the identification of these two TVac-related CpGs, we con-
tinued the analyses to test whether these CpGs affect the preva-
lence of asthma and related markers. We noticed a decreased
prevalence of asthma in vaccinated compared to non-vaccinated
children (Fig. 3). In addition, cg01669161 was also significantly
associated with decreased IgE levels, adding consistencies to our
findings.
There are some limitations to this study. Since DNA-M mea-
surements obtained using the Illumina Infinium HumanMethyla-
tion450 array have high reproducibility and validity [22,36], we
did not technically replicate the DNA-M measurements. Second,
methylation data were obtained from whole blood but not from
specific cell subgroups, due to cost, but also because the differen-
tial methylation observed here may well be present in all cell sub-
sets anyway. Nevertheless, since DNA-M of peripheral blood can be
influenced by the cell composition, we controlled for the cell types
in the EWAS. Third, in the descriptive part, we investigated DNA-M
changes from birth to pregnancy. All individuals with complete
follow-up were women, which restricted our observation of
methylation changes over time to women (Fig. 2). Fourth, the small
sample size at 10 years (n = 30) and the fact that nearly all
6500 V.D. Janjanam et al. / Vaccine 34 (2016) 6493–6501participants (94.3%) were vaccinated at 10 years of age limited our
comparison between vaccinated and non-vaccinated to the age of
18 year. Finally, since this is the first study that demonstrated an
effect of vaccination on asthma that may be mediated via DNA-M
and results in a reduced risk of asthma, further replication of these
associations in an independent cohort is needed.5. Conclusion
In an EWAS, we found that TVac was associated with differen-
tial methylation of two CpG site located in or near genes with func-
tional connections to immunity and antigen presentation. These
CpGs in turn were protective against asthma and increased IgE.
This suggests that DNA-M act as a possible molecular mechanism
of protective effects of TVac against asthma in adolescence. Vacci-
nation and related methylation of specific CpGs may offer novel
prospects to investigate and explain a differential occurrence of
asthma in childhood/adolescence.Funding
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